Are you Dr. Cleary?
Join over one million U.S. Physicians, Nurse Practitioners and PAs, already on Doximity.
- Gain access to free telehealth tools, such as our "call shielding" and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
You already have 106 invites waiting! - Read the latest clinical news, personalized to your specialty.
Office
44 Binney St
Danafarber Cancer Institute
Boston, MA 02115Phone+1 617-632-3000Fax+1 617-632-5370
Summary
- Dr. James Cleary, MD is an oncologist in Boston, Massachusetts. He is currently licensed to practice medicine in Massachusetts, New Hampshire, and Connecticut. He is affiliated with Dana-Farber Cancer Institute, Brigham and Women's Hospital, and Salem Hospital.
Education & Training
Brigham and Women's Hospital/Massachusetts General Hospital/Dana-Farber Cancer InstituteFellowship, Hematology and Medical Oncology, 2006 - 2009
Massachusetts General HospitalResidency, Internal Medicine, 2003 - 2006
Albert Einstein College of MedicineClass of 2003
Certifications & Licensure
FL State Medical License 2022 - Present
MA State Medical License 2005 - 2026
OH State Medical License 2022 - 2026
RI State Medical License 2022 - 2026
VT State Medical License 2022 - 2026
CT State Medical License 2022 - 2025
ME State Medical License 2022 - 2025- American Board of Internal Medicine Medical Oncology
- Join now to see all
Clinical Trials
- A Safety Study of MM-121 With Cetuximab and Irinotecan in Patients With Advanced Cancers Start of enrollment: 2011 Oct 01
- A Safety, Pharmacokinetic and Pharmacodynamic Study of Kevetrin in Patients With Advanced Solid Tumors Start of enrollment: 2012 Oct 01
Publications & Presentations
PubMed
- 112 citationsA phase I study of VS-6063, a second-generation focal adhesion kinase inhibitor, in patients with advanced solid tumors.Suzanne F. Jones, Lillian L. Siu, Johanna C. Bendell, James M. Cleary, Albiruni Ryan Abdul Razak
Investigational New Drugs. 2015-09-04 - 1140 citationsFirst-line nivolumab plus chemotherapy versus chemotherapy alone for advanced gastric, gastro-oesophageal junction, and oesophageal adenocarcinoma (CheckMate 649): a r...Yelena Y. Janjigian, Kohei Shitara, Markus Moehler, Marcelo Garrido, Pamela Salman
Lancet. 2021-07-03 - 4 citationsA Phase I Expansion Cohort Study Evaluating the Safety and Efficacy of the CHK1 Inhibitor LY2880070 with Low-dose Gemcitabine in Patients with Metastatic Pancreatic Ad...Brandon M Huffman, Hanrong Feng, Kalindi Parmar, Junning Wang, Kevin S Kapner
Clinical Cancer Research. 2023-12-15
Press Mentions
Novobiocin Attacks BRCA-Mutated Cancer Cells from Within and Without, Study ShowsMarch 14th, 2023
The Pancreatic Cancer Collective Awards $7 Million in First-Round “New Therapies Challenge” GrantsNovember 20th, 2018
Doctors Hail New Approach in Pancreatic Cancer TreatmentSeptember 12th, 2018
